- Home
- FORA vs CMRX Comparison
FORA vs CMRX Comparison
Compare FORA & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORA
- CMRX
- Stock Information
- Founded
- FORA 2014
- CMRX 2000
- Country
- FORA United States
- CMRX United States
- Employees
- FORA N/A
- CMRX N/A
- Industry
- FORA Computer Software: Prepackaged Software
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- FORA Technology
- CMRX Health Care
- Exchange
- FORA Nasdaq
- CMRX Nasdaq
- Market Cap
- FORA 63.8M
- CMRX 77.0M
- IPO Year
- FORA N/A
- CMRX 2013
- Fundamental
- Price
- FORA $2.10
- CMRX $0.93
- Analyst Decision
- FORA Strong Buy
- CMRX Strong Buy
- Analyst Count
- FORA 1
- CMRX 1
- Target Price
- FORA $5.00
- CMRX $11.00
- AVG Volume (30 Days)
- FORA 14.2K
- CMRX 119.4K
- Earning Date
- FORA 11-07-2024
- CMRX 11-08-2024
- Dividend Yield
- FORA N/A
- CMRX N/A
- EPS Growth
- FORA N/A
- CMRX N/A
- EPS
- FORA 0.06
- CMRX N/A
- Revenue
- FORA $20,371,880.00
- CMRX $144,000.00
- Revenue This Year
- FORA N/A
- CMRX $3,040.12
- Revenue Next Year
- FORA $10.64
- CMRX N/A
- P/E Ratio
- FORA $36.34
- CMRX N/A
- Revenue Growth
- FORA 6.97
- CMRX N/A
- 52 Week Low
- FORA $2.00
- CMRX $0.75
- 52 Week High
- FORA $4.15
- CMRX $1.30
- Technical
- Relative Strength Index (RSI)
- FORA 38.13
- CMRX 60.78
- Support Level
- FORA $2.05
- CMRX $0.80
- Resistance Level
- FORA $2.16
- CMRX $0.98
- Average True Range (ATR)
- FORA 0.05
- CMRX 0.05
- MACD
- FORA 0.00
- CMRX 0.01
- Stochastic Oscillator
- FORA 31.77
- CMRX 83.33
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.